Bristol Myers Squibb announces CAMZYOS approval: Bristol Myers Squibb stock trades EUR 54.42
Published on 10/04/2026 at 18:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb announced on September 30, 2026, that the U.S. Food and Drug Administration approved an expanded indication for CAMZYOS (mavacamten) in adults and pediatric patients weighing at least 30 kilograms. The company said the approval covers symptomatic obstructive hypertrophic cardiomyopathy and was based on Phase 3 SCOUT-HCM results, as reported in its Bristol Myers Squibb release.
At 6:43 p.m. CEST on October 4, 2026, Bristol Myers Squibb stock was at EUR 54.42 in weekend trading at Lang & Schwarz. That was unchanged, or 0.00 percent, versus the EUR 54.42 close at Lang & Schwarz on October 2, 2026.
Weekend trading
The euro price remained aligned with the last Xetra trading-day close. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Last Xetra trading day
Lang & Schwarz recorded a EUR 54.42 closing price for October 2, 2026. Xetra and the primary exchanges were closed during the publication window.
Recent company developments
In a separate September 25, 2026 release, Bristol Myers Squibb reported Phase 3 EXCALIBER-RRMM results for ZENBEXUS (iberdomide) with daratumumab and dexamethasone. Among 420 evaluable patients, the minimal residual disease-negative complete response rate was 41.1 percent with the ZENBEXUS combination versus 20.7 percent with the comparison regimen, according to the company release.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
